Astra Zeneca / Pfizer / GlaxoSmithKline / Forum Working Group / Astra / Schering / Chemokine Antagonist Working Group / Abbott Laboratories / The Forum Chemokine Antagonist Working Group / Antiviral / /
Country
United States / /
Event
FDA Phase / /
Facility
UNIVERSITY SCHOOL OF PUBLIC HEALTH AND HEALTH SERVICES FDA/FCHR Joint Meeting / /
IndustryTerm
HIV treatment / treatment of HIV / /
MedicalCondition
HIV infection / tumor / rapid disease / CCR5 deficiency / HIV / lymphoma / tumors / cardiovascular disease / lymphomas / advanced HIV disease / infectious diseases / symptomatic infection / HIV-RNA / liver disease / infections / West Nile Virus disease / /
MedicalTreatment
antiretroviral treatment / /
Organization
Division of Antiviral Drug Product / Food and Drug Administration’s Division of Antiviral Products / CHEMOKINE ANTAGONIST WORKING GROUP STERRING COMMITTEE / US Food and Drug Administration / FDA / THE GEORGE WASHINGTON UNIVERSITY / /
Person
Jeffrey Murray / Kimberly Struble / Katherine Laessig / Scott Proestel / Lisa Naeger / Deborah Birnkrant / John Fry / Johanna Bogulavsky Grossman Edited / Ipsita Das / Rebecca Griesse / /
Position
Director of the Division / EXECUTIVE / Director of the Division of Products / /
Product
CCR5 / CD4 / /
ProgrammingLanguage
DC / /
Technology
pharmacogenomic / DRUG DEVELOPMENT / Human Genome / /
Buprenorphine in the HIV Primary Care Setting